Bright Minds to discuss BMB-101 phase 2 trial Jan. 6

Mr. Alex Vasilkevich reports BRIGHT MINDS TO ANNOUNCE TOPLINE RESULTS FOR BMB-101 PHASE 2 TRIAL IN ABSENCE SEIZURES AND DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHIES ON TUESDAY, JANUARY 6, 2026 Bright Minds Biosciences Inc. will host a conference call and live webcast at 8 a.m. ET on Jan. 6, 2026, to discuss top-line results for the phase 2 trial of BMB-101 in patients with drug-resistant absence seizures and developmental and epileptic encephalopathy. Webcast information The Bright Minds virtual event will be webcast live, and a replay will be available after the event by visiting the investors section of the company's website and selecting events and presentations. Date and time:  Jan. 6, 2026, at 8 a.m. ET The call will include a discussion of the data followed by a question-and-answer session. Individuals who wish to ask questions should use the questions tab available during the live webcast. About Bright Minds Biosciences Inc. Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Its pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including rare epilepsy, Prader-Willi syndrome, depression and other central nervous system disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives. Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of programs within neurology and psychiatry. We seek Safe Harbor.